Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy

This case series explores the efficacy of baricitinib, a JAK1/2 inhibitor, in treating severe alopecia areata (AA) in 3 patients who previously failed other JAK inhibitor therapies. The study found that baricitinib led to significant hair regrowth in these patients, with improvements in the Severity of Alopecia Tool (SALT) scores. Despite prior failures with JAK inhibitors like tofacitinib and upadacitinib, baricitinib showed potential benefits, suggesting that differences in JAK selectivity and pharmacologic properties may influence treatment outcomes. The study highlights the need for further research to identify patient characteristics that predict better responses to specific JAK inhibitors. Limitations include the small sample size and short follow-up period.